Bcl-xL acts as an inhibitor of IP3R channels, thereby antagonizing Ca2+-driven apoptosis
Nicolas Rosa(University of Geneva), Geert Bultynck(Toxicologie, Pharmacologie et Signalisation Cellulaire), Hideaki Ando(RIKEN Center for Brain Science), Hristina Ivanova(KU Leuven), Kozo Hamada(RIKEN Center for Brain Science), Larry E. Wagner(University of Rochester), Justin Kale(Sunnybrook Hospital), Spyridoula Karamanou(KU Leuven), Joost Schymkowitz(Vrije Universiteit Brussel), Katsuhiko Mikoshiba(ShanghaiTech University), Jan Tavernier(Vlaams Instituut voor Biotechnologie), Anastassios Economou(Rega Institute for Medical Research), Kirsten Welkenhuyzen(VIB-KU Leuven Center for Cancer Biology), Nikolaos Louros(Southwestern Medical Center), David W. Andrews(Seoul National University), Irma Lemmens(Vlaams Instituut voor Biotechnologie), Elien Vandermarliere(VIB-UGent Center for Medical Biotechnology), Victoria Shabardina(Universitat Pompeu Fabra), Jan B. Parys(VIB-KU Leuven Center for Cancer Biology), David I. Yule(University of Rochester), Rita La Rovere(University of Chieti-Pescara), Frédéric Rousseau(Vlaams Instituut voor Biotechnologie)
Cited by 85
Related Papers
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications
|Nature Biotechnology|2002|2.8k
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
|The Lancet|2004|2.4k
BCL-2 family proteins: changing partners in the dance towards death
|Cell Death and Differentiation|2017|1.6k
A Proteome-Scale Map of the Human Interactome Network
|Cell|2014|1.5k